In short
This article discusses clinical trials investigating the use of ExPEC9V, a vaccine containing the active substance ECOO75 (among others), for preventing invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease in older adults. The trials aim to assess the vaccine's efficacy, safety, and immune response in individuals aged 60 and above, particularly those with a history of urinary tract infections.
At a glance
- Vaccine Name
- ExPEC9V (JNJ-78901563)
- Target Population
- Adults aged 60 years and older with a history of urinary tract infections
- Main Objective
- Prevent invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease
- Administration
- Intramuscular injection
- Key Outcomes Measured
- Efficacy in preventing IED events, antibody responses, safety, impact on quality of life
- Study Design
- Randomized, double-blind, placebo-controlled, multicenter Phase 3 study
- Active Substances
- ECOO1A, ECOO2, ECOO4, ECOO6A, ECOO15, ECOO16, ECOO18A, ECOO25B, ECOO75
- Secondary Objectives
- Evaluate efficacy against various E. coli-related infections, assess immunogenicity and safety
What is ECOO75?
ECOO75 is one of the active components in a new vaccine called ExPEC9V (also known as JNJ-78901563) being developed to prevent invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease. ExPEC refers to E. coli bacteria that can cause infections outside the intestines, such as urinary tract infections (UTIs) and more severe invasive infections.
Purpose of ECOO75
ECOO75 is designed to target a specific strain of E. coli (serotype O75) that can cause serious infections. It is part of a vaccine that aims to prevent: Invasive ExPEC disease (IED): This includes infections in the blood or other normally sterile body sites Urinary tract infections (UTIs): Including more severe forms like pyelonephritis (kidney infection) Urosepsis: A life-threatening condition where a UTI leads to a bloodstream infection
Target Population
The ExPEC9V vaccine, which includes ECOO75, is being studied in: Adults aged 60 years and older People with a history of urinary tract infections in the past 2 years Individuals with additional risk factors for invasive E. coli disease, such as: Previous urosepsis or E. coli bloodstream infection Recent hospitalization Conditions that increase the risk of complicated UTIs
Clinical Trials
ECOO75, as part of the ExPEC9V vaccine, is currently being studied in Phase 3 clinical trials. These studies aim to: Evaluate the vaccine's effectiveness in preventing invasive E. coli infections and UTIs Assess the immune response produced by the vaccine Determine the safety and side effects of the vaccine Investigate how the vaccine affects quality of life and health status
Potential Benefits
If successful, the ExPEC9V vaccine containing ECOO75 could potentially: Reduce the incidence of serious E. coli infections, especially in older adults Decrease hospitalizations related to E. coli infections Lower the risk of complications from UTIs, such as kidney infections and sepsis Improve quality of life for individuals prone to recurrent UTIs Help combat antibiotic resistance by preventing infections that would require antibiotic treatment
Safety and Side Effects
As with any vaccine, safety is a crucial aspect being studied in the clinical trials. The researchers are monitoring: Local reactions: Such as pain, redness, or swelling at the injection site Systemic reactions: Including fever, fatigue, or muscle aches Serious adverse events: Any severe or unexpected reactions It's important to note that the full safety profile of the vaccine will only be known after the completion of the clinical trials.
Conclusion
ECOO75, as a component of the ExPEC9V vaccine, represents a promising approach to preventing serious E. coli infections, particularly in older adults and those with a history of UTIs. While the research is still ongoing, this vaccine could potentially have a significant impact on reducing the burden of these infections and improving the quality of life for many individuals. As with any medical treatment, it's essential to consult with healthcare providers for personalized advice and to stay informed about the latest developments in this area of research.